相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Thinking Critically About Classifying Adverse Events: Incidence of Pancreatitis in Patients Treated With Nivolumab plus Ipilimumab
Claire F. Friedman et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2017)
Thinking Critically About Classifying Adverse Events: Incidence of Pancreatitis in Patients Treated With Nivolumab plus Ipilimumab
Claire F. Friedman et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2017)
Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma
Lisa Zimmer et al.
EUROPEAN JOURNAL OF CANCER (2017)
Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials
Dirk Schadendorf et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
Achim Rittmeyer et al.
LANCET (2017)
Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial
Georgina V. Long et al.
LANCET ONCOLOGY (2017)
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
J. D. Wolchok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma
Bert H. O'Neil et al.
PLOS ONE (2017)
CTLA-4 and PD-1 Pathways Similarities, Differences, and Implications of Their Inhibition
Elizabeth I. Buchbinder et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2016)
KEYNOTE-164: Phase II study of pembrolizumab (MK-3475) for patients with previously treated, microsatellite instability-high advanced colorectal carcinoma.
Dung T. Le et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
Louis Fehrenbacher et al.
LANCET (2016)
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
Jonathan E. Rosenberg et al.
LANCET (2016)
Safety and antitumour activity of durvalumab plus tremelimumab in non-small-cell lung cancer: a multicentre, phase 1b study
Scott Antonia et al.
LANCET ONCOLOGY (2016)
Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial
Jeffrey S. Weber et al.
LANCET ONCOLOGY (2016)
Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial
Kei Muro et al.
LANCET ONCOLOGY (2016)
Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial
Scott J. Antonia et al.
LANCET ONCOLOGY (2016)
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
R. L. Ferris et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Martin Reck et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Innovative Clinical Trials: The LUNG-MAP Study
C. E. Steuer et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2015)
Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future
Lieping Chen et al.
JOURNAL OF CLINICAL INVESTIGATION (2015)
Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial
Robert J. Motzer et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
Jeffrey S. Weber et al.
LANCET ONCOLOGY (2015)
Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
Michael A. Postow et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer
Edward B. Garon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer
Julie Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
H. Borghaei et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
Stephen M. Ansell et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Phase I/II study of nivolumab with or without ipilimumab for treatment of recurrent small cell lung cancer (SCLC): CA209-032
Matthew Taylor et al.
Journal for ImmunoTherapy of Cancer (2015)
Immune Escape Mechanisms as a Guide for Cancer Immunotherapy
Gregory L. Beatty et al.
CLINICAL CANCER RESEARCH (2015)
Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy
Janis M. Taube et al.
CLINICAL CANCER RESEARCH (2014)
Development of the National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
Ethan Basch et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2014)
Dual Blockade of PD-1 and CTLA-4 Combined with Tumor Vaccine Effectively Restores T-Cell Rejection Function in Tumors
Jaikumar Duraiswamy et al.
CANCER RESEARCH (2013)
Nivolumab plus Ipilimumab in Advanced Melanoma
Jedd D. Wolchok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
Suzanne L. Topalian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Targeting PD-1/PD-L1 interactions for cancer immunotherapy
Laurence Zitvogel et al.
ONCOIMMUNOLOGY (2012)
Camouflage and sabotage: tumor escape from the immune system
Isabel Poschke et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2011)
Antibodies in oncology
Vinochani Pillay et al.
NEW BIOTECHNOLOGY (2011)
Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion
Robert D. Schreiber et al.
SCIENCE (2011)
PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors
Michael A. Curran et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Therapeutic antibodies: successes, limitations and hopes for the future
Patrick Chames et al.
BRITISH JOURNAL OF PHARMACOLOGY (2009)
Understanding and circumventing resistance to anticancer monoclonal antibodies
Lina Reslan et al.
MABS (2009)
PD-1 and its ligands in tolerance and immunity
Mary E. Keir et al.
ANNUAL REVIEW OF IMMUNOLOGY (2008)
Approved monoclonal antibodies for cancer therapy
Michael Boyiadzis et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2008)
Interaction between B7-H1 and PD-1 determines initiation and reversal of T-cell anergy
Fumihiko Tsushima et al.
BLOOD (2007)
Immune surveillance of tumors
Jeremy B. Swann et al.
JOURNAL OF CLINICAL INVESTIGATION (2007)
Cancer immunoediting from immune surveillance to immune escape
Ryungsa Kim et al.
IMMUNOLOGY (2007)
Tissue expression of PD-L1 mediates peripheral T cell tolerance
ME Keir et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2006)
CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms
RV Parry et al.
MOLECULAR AND CELLULAR BIOLOGY (2005)
Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity
LP Chen
NATURE REVIEWS IMMUNOLOGY (2004)
Cancer immunoediting: from immunosurveillance to tumor escape
GP Dunn et al.
NATURE IMMUNOLOGY (2002)
Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade
Y Iwai et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
HD Dong et al.
NATURE MEDICINE (2002)
The interaction properties of costimulatory molecules revisited
AV Collins et al.
IMMUNITY (2002)
CTLA-4: new insights into its biological function and use in tumor immunotherapy
JG Egen et al.
NATURE IMMUNOLOGY (2002)
B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells
SY Tseng et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2001)
Immunologic self-tolerance maintained by CD25+CD4+ regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4
T Takahashi et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2000)
Structural analysis of CTLA-4 function in vivo
EL Masteller et al.
JOURNAL OF IMMUNOLOGY (2000)
分享论文
